Supplementary Table 2 Differentially expressed lncRNAs identified by RNA-seq

Aim: To explore the expression profiles of lncRNAs and identify novel lncRNAs as biomarkers for early diagnosis and therapy of hepatocellular carcinoma (HCC). Materials & methods: Expression profiles of lncRNAs and mRNAs in five paired HCC and adjacent normal tissues were obtained by RNA-seq. Eight lncRNAs, including two novel liver-specific lncRNAs (NONHSAT059247.2 and NONHSAT013897.2), were validated in another 74 pairs of HCC and adjacent normal tissues by qRT-PCR. Results: The results of qRT-PCR showed that NONHSAT252133.1, NONHSAT112116.2, and NONHSAT242657.1 were significantly upregulated in HCC tissues, whereas NONHSAT169790.1, NONHSAT059247.2, and NONHSAT013897.2 were significantly downregulated. Two liver-specific lncRNAs demonstrated excellent diagnostic performance: NONHSAT059247.2 (AUC=0.941, 95% CI: 0.902-0.979, P Conclusion: The liver-specific lncRNAs NONHSAT059247.2 and NONHSAT013897.2, may provide new biomarkers for the future study on diagnosis, therapy, and mechanisms of HCC.研究目的：探讨长链非编码RNA（long non-coding RNAs, lncRNAs）的表达谱，并筛选可作为肝细胞癌（hepatocellular carcinoma, HCC）早期诊断与治疗生物标志物的新型lncRNAs。 材料与方法：通过RNA测序（RNA-seq）获取5对肝细胞癌组织及其配对癌旁正常组织的lncRNAs与信使RNA（messenger RNA, mRNA）表达谱；采用实时定量聚合酶链式反应（quantitative real-time polymerase chain reaction, qRT-PCR）在另外74对肝细胞癌组织及配对癌旁正常组织中验证8种lncRNAs的表达水平，其中包含2种新型肝特异性lncRNAs（NONHSAT059247.2与NONHSAT013897.2）。 结果：实时定量聚合酶链式反应结果显示，NONHSAT252133.1、NONHSAT112116.2及NONHSAT242657.1在肝细胞癌组织中显著上调，而NONHSAT169790.1、NONHSAT059247.2及NONHSAT013897.2则显著下调。2种肝特异性lncRNAs展现出优异的诊断效能：NONHSAT059247.2（曲线下面积（Area Under Curve, AUC）=0.941，95%置信区间（Confidence Interval, CI）：0.902-0.979，P值未完整标注），结论：肝特异性lncRNAs NONHSAT059247.2与NONHSAT013897.2可为肝细胞癌的诊断、治疗及发病机制研究提供新型生物标志物。